|
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes |
Jun 2025 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Advances and challenges in the treatment of myelodysplastic syndromes |
Jun 2025 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies |
Jun 2025 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy |
Jun 2025 |
Blood Advances |
Aplastic Anemia |
|
What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria? |
May 2025 |
Annals of Hematology |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Towards graft- versus-host disease-free alternative donor transplant platforms for patients with acquired aplastic anemia |
May 2025 |
Haematologica |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
|
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment |
May 2025 |
Turkish Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience |
May 2025 |
Cancers |
Myelodysplastic Syndromes (MDS), Pediatric |
|
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
May 2025 |
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
|
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
Apr 2025 |
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
